Financial Performance - The company achieved an operating revenue of 925 million RMB, representing an 18.18% increase compared to the previous year [3] - The comprehensive gross profit margin was 71.31%, an increase of 1.09 percentage points year-on-year [3] - The adjusted net profit attributable to the parent company was approximately 182 million RMB, meeting the budget target for the year [3] Business Strategy - The company implemented a "3+2" market development strategy focusing on three key industries: peptides, bispecific antibodies/ADC, and blood products, while also exploring opportunities in vaccines and small nucleic acids [4] - Sales revenue from core business products, chromatography fillers and media, reached 552 million RMB, a growth of 22.57% year-on-year [4] - International business revenue was approximately 84 million RMB, showing a significant growth of about 78% [4] Research and Development - The company increased its R&D investment to 197 million RMB, an 11.12% increase from the previous year, accounting for 21.29% of the annual operating revenue [5] Profitability Improvement - Operating profit and total profit increased by 88.48% and 87.51% respectively, outpacing the growth rate of operating revenue [7] - The net profit attributable to the parent company grew by 64.18%, while the net profit excluding non-recurring gains and losses increased by 78.55% [7]

Core Insights - The A-share biopharmaceutical companies are expected to deliver innovative results in 2025, benefiting from industry recovery, overseas market expansion, and favorable pharmaceutical policies [2] - Over 90 A-share biopharmaceutical companies have released performance forecasts for 2025, with 53 companies expected to be profitable [2] - Among the profit forecasts, 14 companies anticipate a net profit increase of over 100%, while 10 companies expect to turn losses into profits [3][2] Group 1: Performance Growth Drivers - Sales volume growth and internal cost reduction are key factors for the significant profit increases among the companies [4] - Shanghai Yizhong leads with a projected net profit increase of 760.18% to 903.54%, expecting a net profit of 60 million to 70 million yuan in 2025 due to its core product being included in the national medical insurance directory [4] - Yuheng Pharmaceutical anticipates a net profit of 350 million to 420 million yuan, a year-on-year increase of 50.37% to 80.44%, driven by steady sales growth of its products [4] - Nawei Technology expects a net profit of 128 million to 145 million yuan, a year-on-year increase of 54.51% to 75.03%, focusing on market strategies in key sectors [4][5] Group 2: International Market Expansion - International business is a significant growth driver for biopharmaceutical companies [6] - WuXi AppTec, a leading CXO company, forecasts a revenue of 45.456 billion yuan, a year-on-year increase of approximately 15.84%, and a net profit of 19.151 billion yuan, a 102.65% increase [6] - Ganli Pharmaceutical expects a net profit of 1.1 billion to 1.2 billion yuan, a year-on-year increase of 78.96% to 95.23%, attributed to steady growth in domestic and international revenues [6] Group 3: Innovation and Recovery - Several innovative drug companies are entering a recovery phase, with many turning losses into profits or significantly reducing losses [8] - BeiGene expects a full-year operating profit for 2025, with revenue projections between 36.2 billion and 38.1 billion yuan, reflecting an upward adjustment from previous estimates [8] - DiZhe Pharmaceutical anticipates a revenue of 800 million yuan, a year-on-year increase of 122.28%, with a reduced net loss of 770 million yuan [9]

Core Viewpoint - Nanwei Technology expects a significant increase in net profit for 2025, projecting a growth of 54.51% to 75.03% year-on-year, driven by strategic market development and product innovation [1] Financial Performance - The company forecasts a net profit attributable to shareholders of 128 million to 145 million yuan for 2025 [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between 112 million and 128 million yuan, reflecting a year-on-year increase of 70.02% to 94.31% [1] Business Strategy - The company is implementing a "3+2" market development strategy focusing on three key sectors: peptides, bispecific antibodies/ADC, and blood products, while also exploring growth opportunities in vaccines and small nucleic acids [1] - The strategy aims to enhance competitive advantages through technological innovation of key products and quality improvements [1] Sales Growth - Sales revenue from core products, including chromatographic fillers and chromatography media, has increased by approximately 23% this year [1] - Sales revenue from liquid chromatography columns and sample preparation products has seen a growth of about 32% [1] International Expansion - The company is intensifying efforts to expand into international markets, enhancing its overseas marketing system and strengthening sales capabilities [1] - International business revenue reached approximately 84 million yuan, marking a year-on-year increase of about 79% [1]

Core Viewpoint - Nanwei Technology (688690) expects to achieve a net profit attributable to shareholders of the parent company between 128 million yuan and 145 million yuan for the fiscal year 2025, representing a year-on-year growth of 54.51% to 75.03% [1] Group 1: Financial Performance - The company's core business in chromatographic fillers and chromatography media products saw a sales revenue increase of approximately 23% [1] - Sales revenue for liquid chromatography columns and sample pre-treatment products experienced an increase of about 32% [1]

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company's core business is showing positive operational trends, with significant growth in overseas market expansion opportunities [1][6] - The company reported a revenue of 414 million yuan for H1 2025, representing a year-on-year growth of 21.74%, and a net profit of 63 million yuan, up 40.52% year-on-year [1][2] Revenue and Profit Analysis - Revenue growth is recovering, with a notable performance in profits. Excluding the impact of Fuli Instruments in January and February 2025, the revenue growth for H1 2025 is 16.20% year-on-year [2] - The core business of chromatography fillers and media generated revenue of 238 million yuan, a growth of approximately 20% year-on-year [2][3] - The overall gross margin for H1 2025 was 72.06%, a slight decrease of 0.36 percentage points year-on-year, primarily due to the consolidation of Fuli Instruments [2] Business Segment Performance - The chromatography fillers and media segment saw a revenue of 238 million yuan, with significant contributions from small molecule drugs, particularly driven by the demand for GLP-1 and other peptide drugs, which achieved a revenue of 75 million yuan, growing 108% year-on-year [3][5] - The company has established strong strategic partnerships, with sales from signed biopharmaceutical clients reaching 108 million yuan, accounting for about 45% of the chromatography fillers business revenue [5] International Market Expansion - The company is actively expanding its international market presence, with international revenue for H1 2025 reaching 44 million yuan, a year-on-year increase of approximately 136% [6] - The company is well-positioned to benefit from the increasing number of domestic innovative drug companies expanding overseas, potentially entering the supply chains of large multinational corporations [6] Financial Forecast - The company is projected to achieve revenues of 984 million yuan, 1.212 billion yuan, and 1.496 billion yuan for the years 2025, 2026, and 2027, respectively, with corresponding net profits of 142 million yuan, 214 million yuan, and 284 million yuan [8] - The estimated EPS (diluted) for the years 2025, 2026, and 2027 are 0.35 yuan, 0.53 yuan, and 0.70 yuan, respectively, with corresponding P/E ratios of 82.27, 54.62, and 41.20 [8]

Group 1 - The company reported a revenue of 782 million yuan for 2024, representing a year-on-year growth of 33.33%, with a net profit attributable to the parent company of 83 million yuan, up 20.82% year-on-year [1] - In Q1 2025, the company achieved a revenue of 189 million yuan, a year-on-year increase of 22.39%, and a net profit attributable to the parent company of 29 million yuan, up 72.98% year-on-year [1] - The core business of chromatography fillers and media generated a revenue of 451 million yuan in 2024, with a year-on-year growth of 10.20% [2] Group 2 - The newly added chromatography analysis instruments and accessories contributed a revenue of 154 million yuan, primarily from the consolidation of the acquired company Fuli Instruments [2] - The market for chromatography fillers is expanding, with a current domestic market penetration rate of only about 10%, indicating significant potential for domestic substitution [3] - The company has established strategic cooperation agreements with five major clients, resulting in a sales volume of 224 million yuan, accounting for 50% of the revenue from chromatography fillers [3] Group 3 - The company is evolving into a leading domestic supplier of chromatography fillers, consumables, and instruments, driven by underlying technology [4] - Revenue projections for 2025-2027 are 977 million yuan, 1.17 billion yuan, and 1.37 billion yuan, with net profits of 134 million yuan, 203 million yuan, and 290 million yuan respectively [4] - The current stock price corresponds to a PE ratio of 67, 45, and 31 times for 2025-2027 [4]